When should milrinone be discontinued?

When to Stop Milrinone

Milrinone should be discontinued once the patient's clinical status has stabilized and an adequate oral medication regimen has been established that maintains symptomatic improvement—typically requiring observation for at least 48 hours after stopping the infusion to confirm tolerability of the oral strategy. 1, 2, 3

Primary Indications for Discontinuation

1. Successful Transition to Oral Therapy (Standard Approach)

Once hemodynamic stability is achieved in acute decompensated heart failure, every effort should be made to wean to an oral regimen. The adequacy and tolerability of oral-based strategies necessitates hospital observation for at least 48 hours after milrinone discontinuation 1, 2, 3. This is the preferred endpoint for most patients.

2. Immediate Discontinuation for Safety Concerns

Stop milrinone immediately if:

• Excessive hypotension develops (systolic BP <90 mmHg with poor perfusion despite vasopressor support) 4
• Severe arrhythmias occur, particularly sustained ventricular tachycardia 4
• Infusion site reactions or extravasation are identified 4
• Therapy-resistant worsening renal function with doubling of serum creatinine or absolute creatinine >3.5 mg/dL 5

The FDA label explicitly states that infusion should be "reduced or temporarily discontinued" when hypotension occurs due to milrinone's vasodilator effects 4.

3. Duration Limitations

There is no controlled trial experience with milrinone infusions exceeding 48 hours 4. While the drug is used for longer periods in clinical practice (particularly as bridge to transplant), this represents off-label use beyond the evidence base. The 2020 ESC guidance recommends using the "lowest dose possible + shortest duration possible" for inotropes 5.

Special Circumstances for Continued Use

Continuous Infusion (Palliative or Bridge Therapy)

Milrinone may be continued long-term only in highly selected scenarios:

• Bridge to cardiac transplantation: Patients awaiting transplant who cannot be weaned despite repeated attempts 1, 2, 3
• Palliative care: As part of end-of-life symptom management to allow comfortable death at home 1, 2, 3

Critical caveat: The decision for continuous home infusion should not be made until all alternative attempts to achieve stability have failed repeatedly, as this approach presents major burden to families and healthcare services and may ultimately increase mortality risk 1, 2, 3.

What NOT to Do

Intermittent outpatient infusions of milrinone have not shown benefit for symptoms or survival in advanced heart failure and should be avoided 1, 2. This differs from continuous infusion for bridge/palliation.

Monitoring During Weaning

When discontinuing milrinone:

• Monitor blood pressure and heart rate continuously 4
• Assess for return of congestion or low cardiac output symptoms
• Check renal function and electrolytes (particularly potassium, as diuresis may have caused depletion) 4
• Observe for at least 48 hours on oral regimen before discharge 1, 2, 3

Context-Specific Considerations

In ischemic heart failure: The OPTIME-CHF trial showed higher death/rehospitalization rates with milrinone in ischemic etiology (42% vs 36% placebo, p=0.01) 6. Consider earlier discontinuation in this population.

With beta-blockers: Milrinone's mechanism (phosphodiesterase inhibition) is not antagonized by beta-blockade, making it preferred over dobutamine when patients are on beta-blockers 7. However, this doesn't change discontinuation timing—still aim for transition to oral therapy once stable.

Avoid in acute MI: Milrinone is not recommended in the acute phase post-myocardial infarction until further clinical experience is gained 4.

Practical Algorithm for Discontinuation

1. Assess clinical stability: Resolution of hypoperfusion signs, adequate urine output, stable vital signs
2. Optimize oral regimen: Ensure ACE inhibitors/ARBs, beta-blockers, diuretics are appropriately dosed
3. Gradual wean: Reduce milrinone dose incrementally while monitoring hemodynamics
4. 48-hour observation: Keep patient hospitalized for 48 hours after complete discontinuation
5. If decompensation occurs: Resume milrinone and reassess candidacy for mechanical support or transplant

The overarching principle is that milrinone is a temporizing measure for acute stabilization, not a chronic therapy except in end-stage scenarios where no other options exist.